

# **Erythropoietin Drugs Market by Product Types (Epoetin-alfa, Epoetin-beta, Darbepoetin-alfa) and Applications (Anemia, Kidney Disorders, Neural Disease and Wound healing) - Global Opportunity Analysis and Industry Forecast, 2013 - 2020**

<https://marketpublishers.com/r/G22EFD8A71AEN.html>

Date: January 2015

Pages: 115

Price: US\$ 4,999.00 (Single User License)

ID: G22EFD8A71AEN

## **Abstracts**

Erythropoietin is a glycoprotein hormone synthesized in the bone marrow that controls and regulates the mechanism of erythropoiesis (production of red blood cells). These erythropoietin (EPO) drugs are used for treatment of chemotherapy-induced anemia; anemia is a common side-effect occurring due to chemotherapy of End Stage Renal Diseases (ESRD), cancer and HIV. Improved recombinant DNA technology has led to development of synthetic forms of erythropoietin such as epoetin alfa, epoetin beta, darbepoetin alfa, epoetin omega, and epoetin delta among the others. The global EPO drugs market is thus driven by increasing number of patients suffering from anemic condition induced due to cancer, HIV and ESRD treatment; favorable reimbursements and increasing commercialization of EPO biosimilars. The global EPO drugs market would reach \$11.9 billion by 2020, registering CAGR of 9.7% during 2014-2020. Amongst all synthetic erythropoietin products, Epoetin alfa and its advance version, Darbepoetin alfa, are the most popular drugs. Epoetin alfa and Darbepoetin alfa collectively accounted for ~80% of total EPO drugs market revenue. Amgen Inc. was first company to innovate Epoetin alfa and Darbepoetin alfa that are branded/patented as Epogen and Aranesp respectively. However, expiration of Amgen's patent for Epogen has aided manufacturers of biosimilars to enter the EPO drugs market. Availability of numerous biosimilars has rendered low-cost option to the patients, therefore increased adoption rates for EPO drugs particularly in the developing regions. Based on the applications, the global EPO drugs market is segmented into anemia associated with End Stage Renal Diseases (ESRD), cancer chemotherapy and, antiretroviral treatment (ART). Current research is focused toward expanding the

applications of EPO drugs in other disease conditions such as neural diseases and wound healing.

Global EPO drugs market is segmented based on geography into North America, Europe, Asia Pacific and LAMEA. Europe is the leading geographical market owing to favorable reimbursement policies and less stringent and speedy regulatory approvals for EPO drugs.

Key companies profiled in the report are, Amgen Inc., Johnson & Johnson, Hospira Inc., Roche, LG Life Sciences Ltd., Biocon, Intas Pharmaceuticals, Teva Pharmaceutical Industries Ltd., Ranbaxy Laboratories Ltd., and Celltrion, Inc.

Global Erythropoietin Drugs Market sidebar

## **KEY BENEFITS**

An in-depth analysis of current research and clinical developments within EPO drugs market is provided with key market dynamic factors that helps in understanding the behavior of market

The report provides the quantitative analysis of the current market and estimations through 2013-2020 that assists in identifying the prevailing market opportunities to capitalize on

Extensive analysis of the market is conducted by closely following key product positioning and monitoring the top contenders within the market framework

Comprehensive analysis of all geographic regions are provided that helps in determining the prevailing opportunities in these geographies

Key market players within the EPO drugs market are profiled in the report and their strategies are analyzed thoroughly, which helps in understanding competitive outlook of global EPO drugs market

## **MARKET SEGMENTATION**

The global EPO drugs market is segmented based on products, applications and geography.

### **MARKET BY PRODUCT TYPES**

Epoetin-alfa

Epoetin-beta

Darbepoetin-alfa

## MARKET BY APPLICATIONS

Anemia (Cancer and HIV treatment)

Kidney Disorders (ESRD and Dialysis)

Others (Neural Disease and Wound healing)

## MARKET BY GEOGRAPHY

North America

Europe

Asia-Pacific

LAMEA

## Contents

### CHAPTER 1 INTRODUCTION

- 1.1 Key Benefits
- 1.2 Key Market Segments
- 1.3 Research Methodology
  - 1.3.1 Primary Research
  - 1.3.2 Secondary Research
  - 1.3.3 Analyst tools and models

### CHAPTER 2 EXECUTIVE SUMMARY

- 2.1 Market beyond what to expect by 2025 (\$Million)
  - 2.1.1 Moderate growth scenario
  - 2.1.2 Rapid growth scenario
  - 2.1.3 Diminishing growth scenario

### CHAPTER 3 MARKET OVERVIEW

- 3.1 Market definition and scope
- 3.2 Evolution of Erythropoietin drugs
- 3.3 Erythropoietin Omega and Delta: pruned R&D pipeline drugs
- 3.4 Ethical considerations of erythropoietin drugs
- 3.5 Key findings
  - 3.5.1 Top Factors Impacting for Global Erythropoietin Drugs Market
  - 3.5.2 Top Investment Pockets for Global Erythropoietin Drugs Market
- 3.6 Value Chain Analysis
- 3.7 Key market player positioning (2014)
- 3.8 Product positioning for patented products (2014)
- 3.9 Clinical trials for EPO drug in neural diseases and wound healing
- 3.10 Competitive Intelligence on top three leaders (Amgen, J&J and Roche)
- 3.11 Market share analysis, 2013
- 3.12 Market dynamics
  - 3.12.1 Drivers
    - 3.12.1.1 Increasing number cases: including cancer, HIV, kidney disease and anaemia
    - 3.12.1.2 Growing trends of commercialization for erythropoietin biosimilars
    - 3.12.1.3 Readily available reimbursements and favorable government regulations

- 3.12.1.4 Increasing level of awareness about the benefits of EPO therapeutics
- 3.12.2 Restraints
  - 3.12.2.1 Unaffordability of therapeutics
  - 3.12.2.2 Longer duration of treatments
  - 3.12.2.3 Adverse amount of side effects
- 3.12.3 Opportunities
  - 3.12.3.1 Commercialization of darbepoetin alfa biosimilar
  - 3.12.3.2 Achieving Economies of scale across developed region with biosimilar version of EPO

## **CHAPTER 4 GLOBAL ERYTHROPOIETIN MARKET BY PRODUCTS**

- 4.1 Epoetin-alfa
  - 4.1.1 Historical Milestones
  - 4.1.2 Commercial outlook
  - 4.1.3 Approaches of clinical trials
  - 4.1.4 Key market trends
  - 4.1.5 Regulatory and reimbursement scenarios
  - 4.1.6 Key growth factors and opportunities
  - 4.1.7 Market size and forecast
- 4.2 Epoetin-beta
  - 4.2.1 Historical Milestones
  - 4.2.2 Approaches of clinical trials
  - 4.2.3 Key market trends
  - 4.2.4 Regulatory and reimbursement scenarios
  - 4.2.5 Key growth factors and opportunities
  - 4.2.6 Market size and forecast
- 4.3 Darbepoetin-alfa
  - 4.3.1 Historical Milestones
  - 4.3.2 Commercial outlook
  - 4.3.3 Approaches of clinical trials
  - 4.3.4 Key market trends
  - 4.3.5 Regulatory and reimbursement scenarios
  - 4.3.6 Key growth factors and opportunities
  - 4.3.7 Market size and forecast

## **CHAPTER 5 GLOBAL ERYTHROPOIETIN MARKET BY APPLICATIONS**

- 5.1 Anemia (Cancer and HIV treatment)

- 5.2 Kidney Disorders (ESRD and Dialysis)
- 5.3 Others (Neural Disease and Wound healing)

## **CHAPTER 6 GLOBAL ERYTHROPOIETIN MARKET BY GEOGRAPHY**

- 6.1 North America
  - 6.1.1 Key market trends
  - 6.1.2 Reimbursement and regulations
  - 6.1.3 Key growth factors and opportunities
  - 6.1.4 Market size and forecast
- 6.2 Europe
  - 6.2.1 Key market trends
  - 6.2.2 Reimbursement and regulations
  - 6.2.3 Key growth factors and opportunities
  - 6.2.4 Market size and forecast
- 6.3 Asia-Pacific
  - 6.3.1 Key market trends
  - 6.3.2 Reimbursement and regulations
  - 6.3.3 Key growth factors and opportunities
  - 6.3.4 Market size and forecast
- 6.4 LAMEA
  - 6.4.1 Key market trends
  - 6.4.2 Reimbursement and regulations
  - 6.4.3 Key growth factors and opportunities
  - 6.4.4 Market size and forecast

## **CHAPTER 7 COMPANY PROFILES**

- 7.1 Amgen Inc.
  - 7.1.1 Overview
  - 7.1.2 Amgen Inc. snapshot
  - 7.1.3 Financial performance
  - 7.1.4 Operating Business Segment
  - 7.1.5 SWOT analysis
- 7.2 Johnson and Johnson
  - 7.2.1 Company overview
  - 7.2.2 Johnson & Johnson snapshot
  - 7.2.3 Operating Business Segment Overview
  - 7.2.4 Financial performance

- 7.2.1 SWOT Analysis
- 7.3 Roche
  - 7.3.1 Company overview
  - 7.3.2 Roche Diagnostics snapshot
  - 7.3.3 Operating Business Segment Overview
  - 7.3.4 Financial performance
  - 7.3.5 SWOT analysis of Roche Diagnostics
- 7.4 Hospira
  - 7.4.1 Company overview
  - 7.4.2 Hospira snapshot
  - 7.4.3 Operating Business Segment Overview
  - 7.4.4 Financial performance
  - 7.4.5 SWOT analysis of Hospira
- 7.5 LG Life Sciences Ltd.
  - 7.5.1 Company overview
  - 7.5.2 LG Life Sciences Ltd. snapshot
  - 7.5.3 Operating Business Segment Overview
  - 7.5.4 Financial performance
  - 7.5.5 SWOT analysis of LG Life Sciences Ltd.
- 7.6 Biocon
  - 7.6.1 Company overview
  - 7.6.2 Biocon snapshot
  - 7.6.3 Operating Business Segment Overview
  - 7.6.4 Financial performance
  - 7.6.5 SWOT analysis of Biocon
- 7.7 Intas Pharmaceuticals
  - 7.7.1 Company overview
  - 7.7.2 Intas Pharmaceuticals snapshot
  - 7.7.3 Operating Business Segment Overview
  - 7.7.4 Financial performance
  - 7.7.5 SWOT analysis of Intas Pharmaceuticals
- 7.8 Teva Pharmaceutical Industries Ltd.
  - 7.8.1 Company overview
  - 7.8.2 Teva Pharmaceutical Industries Ltd. snapshot
  - 7.8.3 Operating Business Segment Overview
  - 7.8.4 Financial performance
  - 7.8.5 SWOT analysis of Teva Pharmaceutical Industries Ltd.
- 7.9 Ranbaxy Laboratories Ltd.
  - 7.9.1 Company overview

7.9.2 Ranbaxy Laboratories Ltd. snapshot

7.9.3 Operating Business Segment Overview

7.9.4 Financial performance

7.9.5 SWOT analysis of Ranbaxy Laboratories Ltd.

7.10 Celltrion, Inc

7.10.1 Company overview

7.10.2 Celltrion, Inc. snapshot

7.10.3 Operating Business Segment Overview

7.10.4 Financial performance

7.10.5 SWOT analysis of Celltrion, Inc.



## List Of Tables

### LIST OF TABLES

TABLE 1 GLOBAL ERYTHROPOIETIN MODERATE GROWTH SCENARIO BY GEOGRAPHY, 2020-2025 (\$MILLION)

TABLE 2 GLOBAL ERYTHROPOIETIN RAPID GROWTH SCENARIO BY GEOGRAPHY, 2020-2025 (\$MILLION)

TABLE 3 GLOBAL ERYTHROPOIETIN DIMINISHING GROWTH SCENARIO BY GEOGRAPHY, 2020-2025 (\$MILLION)

TABLE 4 ERYTHROPOIETIN DRUGS (COMPANIES, BRAND NAME, AND VARIANTS)

TABLE 5 CLINICAL TRIALS OF ERYTHROPOEITIN FOR NEURAL DISEASES AND WOUND HEALING

TABLE 6 COMPETITIVE INTELLIGENCE ON TOP THREE LEADERS IN ERYTHROPOIETIN MARKET

TABLE 7 BIOSIMILAR VERSION OF ERYTHROPOIETIN COMMERCIALIZED AND UNDER DEVELOPMENT

TABLE 8 CMS REIMBURSEMENT CODES FOR ERYTHROPOIETIN

TABLE 9 ORIGINATOR EPOTIN ALFA PRODUCTS AND THEIR REVENUES IN 2013

TABLE 10 BIOSIMILARS OF EPOETIN ALFA: APPROVED OR IN DEVELOPMENT PHASE

TABLE 11 CLINICAL TRIALS OF EPOETIN ALFA

TABLE 12 CMS POLICY CODES FOR EPOETIN ALFA

TABLE 13 EPOTIN BETA PRODUCTS AND THEIR REVENUES (2013)

TABLE 14 CLINICAL TRIALS FOR EPOETIN BETA

TABLE 15 CMS POLICY CODES FOR EPOETIN BETA

TABLE 16 BIOSIMILARS OF DARBEPOETIN ALFA

TABLE 17 CLINICAL TRIALS FOR DARBEPOETIN ALFA

TABLE 18 CMS POLICY CODES FOR DARBEPOETIN ALFA

TABLE 19 GLOBAL CANCER AND HIV INDUCED ANEMIA ERYTHROPOIETIN DRUGS APPLICATION MARKET BY GEOGRAPHY, 2013-2020, \$MILLION

TABLE 20 DIALYSIS POPULATION GROWTH RATE IN 2013

TABLE 21 ESTIMATED (ESRD PATIENT) POPULATION BASE TAKING EPO THERAPY, 2013-2020, (THOUSAND)

TABLE 22 GLOBAL ESRD AND DIALYSIS INDUCED ANEMIA ERYTHROPOIETIN DRUGS APPLICATION MARKET BY GEOGRAPHY, 2013-2020, \$MILLION

TABLE 23 GLOBAL NEURAL DISEASES AND WOUND HEALING INDUCED ANEMIA ERYTHROPOIETIN DRUG APPLICATION MARKET BY GEOGRAPHY, 2013-2020,

\$MILLION

TABLE 24 GLOBAL ERYTHROPOETIN MARKET BY GEOGRAPHY, 2013 – 2020  
(\$MILLION)

TABLE 25 SYNTHETIC ERYTHROPOIETIN MARKETING IN UNITED STATES

TABLE 26 REVISED USFDA GUIDELINES FOR THE DOSING OF ERYTHROPOIETIN  
STIMULATING AGENTS

TABLE 27 CMS POLICY DECISIONS FOR THE REIMBURSEMENT OF  
ERYTHROPOIETIN STIMULATING AGENTS

TABLE 28 NORTH AMERICA ERYTHROPOETIN MARKET BY PRODUCT TYPES,  
2013 – 2020 (\$MILLION)

TABLE 29 EMA APPROVED ERYTHROPOIETIN (BIOSIMILARS AND INNOVATOR  
PRODUCTS) IN EUROPE

TABLE 30 EUROPE ERYTHROPOETIN MARKET BY PRODUCT TYPES, 2013 – 2020  
(\$MILLION)

TABLE 31 BIOSIMILARS MARKETING IN ASIA-PACIFIC

TABLE 32 ASIA-PACIFIC ERYTHROPOETIN MARKET BY PRODUCT TYPES, 2013 –  
2020 (\$MILLION)

TABLE 33 LAMEA ERYTHROPOETIN MARKET BY PRODUCT TYPES, 2013 – 2020  
(\$MILLION)

TABLE 34 AMGEN INC. SNAPSHOT

TABLE 35 AMGEN INC. OPERATING BUSINESS SEGMENT

TABLE 36 JOHNSON & JOHNSON SNAPSHOT

TABLE 37 JOHNSON AND JOHNSON OPERATING SEGEMENTS

TABLE 38 ROCHE SNAPSHOT

TABLE 39 ROCHE OPERATING SEGEMENTS

TABLE 40 HOSPIRA SNAPSHOT

TABLE 41 HOSPIRA OPERATING SEGEMENTS

TABLE 42 LG LIFE SCIENCES LTD. DIAGNOSTICS SNAPSHOT

TABLE 43 LG LIFE SCIENCES LTD. DIAGNOSTICS OPERATING SEGEMENTS

TABLE 44 BIOCON SNAPSHOT

TABLE 45 BIOCON OPERATING SEGEMENTS

TABLE 46 INTAS PHARMACEUTICALS SNAPSHOT

TABLE 47 INTAS PHARMACEUTICALS OPERATING SEGEMENTS

TABLE 48 TEVA PHARMACEUTICAL INDUSTRIES LTD. SNAPSHOT

TABLE 49 TEVA PHARMACEUTICAL INDUSTRIES LTD. OPERATING SEGEMENTS

TABLE 50 RANBAXY LABORATORIES LTD. SNAPSHOT

TABLE 51 RANBAXY LABORATORIES LTD. OPERATING SEGEMENTS

TABLE 52 CELLTRION, INC. SNAPSHOT

TABLE 53 CELLTRION, INC. OPERATING SEGEMENTS



## List Of Figures

### LIST OF FIGURES

FIG. 1 IMPACT ANALYSIS OF GLOBAL ERYTHROPOIETIN MARKET IN MODERATE GROWTH SCENARIO

FIG. 2 IMPACT ANALYSIS OF GLOBAL ERYTHROPOIETIN MARKET IN RAPID GROWTH SCENARIO

FIG. 3 IMPACT ANALYSIS OF GLOBAL ERYTHROPOIETIN MARKET IN DIMINISHING GROWTH SCENARIO

FIG. 4 GLOBAL ERYTHROPOIETIN (EPO) DRUGS MARKET DEFINITION

FIG. 5 EVOLUTION OF ERYTHROPOIETIN DRUGS

FIG. 6 TOP IMPACTING FACTORS OF GLOBAL ERYTHROPOIETIN DRUGS MARKET (2013-2020)

FIG. 7 TOP INVESTMENT POCKETS FOR GLOBAL ERYTHROPOIETIN DRUGS MARKET

FIG. 8 ERYTHROPOIETIN (EPO) VALUE CHAIN BY APPLICATION

FIG. 9 MARKET PLAYER POSITIONING OF ERYTHROPOIETIN DRUGS MARKET, 2014, (MILLION)

FIG. 10 ERYTHROPOIETIN PATENTED PRODUCT POSITIONING (2014)

FIG. 11 MARKET SHARE ANALYSIS OF GLOBAL ERYTHROPOIETIN DRUGS MARKET (2013)

FIG. 12 REGIONAL SALES OF NEORECORMON AND MIRCERA IN 2013 (\$ MILLION)

FIG. 13 FORECAST ADOPTION OF EPO THERAPY BY GEOGRAPHY, 2013-2020 (% RATE)

FIG. 14 FINANCIAL REVENUE OF AMGEN INC. BY GEOGRAPHY (2013)

FIG. 15 FINANCIAL REVENUE OF AMGEN INC. BY PRODUCT PORTFOLIO (2013)

FIG. 16 SWOT ANALYSIS OF AMGEN INC.

FIG. 17 FINANCIAL REVENUE OF JOHNSON & JOHNSON BY GEOGRAPHY (2013)

FIG. 18 FINANCIAL REVENUE OF JOHNSON & JOHNSON BY BUSINESS UNITS (2013)

FIG. 19 SWOT ANALYSIS OF JOHNSON & JOHNSON

FIG. 20 FINANCIAL REVENUE OF ROCHE DIAGNOSTICS BY GEOGRAPHY (2013)

FIG. 21 FINANCIAL REVENUE OF ROCHE DIAGNOSTICS BY BUSINESS UNITS (2013)

FIG. 22 SWOT ANALYSIS OF ROCHE DIAGNOSTICS

FIG. 23 FINANCIAL REVENUE OF ROCHE DIAGNOSTICS BY GEOGRAPHY (2013)

FIG. 24 FINANCIAL REVENUE OF ROCHE DIAGNOSTICS BY BUSINESS UNITS

(2013)

FIG. 25 SWOT ANALYSIS OF ROCHE

FIG. 26 SWOT ANALYSIS OF LG LIFE SCIENCES LTD.

FIG. 27 SWOT ANALYSIS OF HOSPIRA

FIG. 28 SWOT ANALYSIS OF INTAS PHARMACEUTICALS

FIG. 29 SWOT ANALYSIS OF TEVA PHARMACEUTICAL INDUSTRIES LTD.

FIG. 30 SWOT ANALYSIS OF RANBAXY LABORATORIES LTD.

FIG. 31 SWOT ANALYSIS OF CELLTRION, INC.

## I would like to order

Product name: Erythropoietin Drugs Market by Product Types (Epoetin-alfa, Epoetin-beta, Darbepoetin-alfa) and Applications (Anemia, Kidney Disorders, Neural Disease and Wound healing) - Global Opportunity Analysis and Industry Forecast, 2013 - 2020

Product link: <https://marketpublishers.com/r/G22EFD8A71AEN.html>

Price: US\$ 4,999.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/G22EFD8A71AEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:

Last name:

Email:

Company:

Address:

City:

Zip code:

Country:

Tel:

Fax:

Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below

and fax the completed form to +44 20 7900 3970